Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Spruce Biosciences, Inc. - Common Stock
(NQ:
SPRB
)
54.37
+0.36 (+0.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Spruce Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Tuesday's session: top gainers and losers
↗
April 15, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
April 15, 2025
Via
Benzinga
The market is filled with gapping stocks in Tuesday's session.
↗
April 15, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Via
Chartmill
Crude Oil Moves Lower; Citigroup Posts Upbeat Results
↗
April 15, 2025
Via
Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
↗
April 15, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Nasdaq Surges 100 Points; Bank of America Earnings Top Views
↗
April 15, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
April 15, 2025
Via
Benzinga
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
April 15, 2025
From
Spruce Biosciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 31, 2025
Via
Benzinga
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
↗
December 11, 2024
Spruce Biosciences discontinues tildacerfont trials for CAH as CAHmelia-204 misses primary endpoint and CAHptain-205 shows dose-dependent trends.
Via
Benzinga
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
December 10, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 11, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
October 28, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024
↗
August 12, 2024
SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 12, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
July 11, 2024
Via
AB Newswire
Spruce Biosciences Recognized as a Bay Area Best Place to Work
June 06, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
↗
June 04, 2024
Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.
Via
Benzinga
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
June 04, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
June 03, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
May 23, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
May 22, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024
↗
May 13, 2024
SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 13, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in May Investor Conferences
May 01, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Pfizer Q1 Earnings and Revenues Beat Estimates
↗
May 01, 2024
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago.
Via
Talk Markets
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
April 30, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
April 22, 2024
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
